Genovus Biotechnologies INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersLouisville, CO
US patents5
SAM.gov UEIQC6WVN2CNHC9
CAGE code805Q0
Incorporated inCO
- biophysical technology-based treatments
- major illness
- muscle dysfunction
- orthopedic concerns
- neuromuscular injuries
- Social responsibility
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit OrganizationWoman Owned BusinessWoman Owned Small Business
Self-certified by the company in its SAM.gov registration
Patents
5 US patents granted 2019–2023, 4 of them in the five years to SEP 2025.
Medical technology 5
- Muscle optimization device and methodUS 11,793,716 · granted OCT 24, 2023
- Muscle optimization device and methodUS 11,633,618 · granted APR 25, 2023
- Muscle optimization device and methodUS 11,246,799 · granted FEB 15, 2022
- Muscle optimization device and methodUS 10,888,707 · granted JAN 12, 2021
- Muscle optimization device and methodUS 10,322,063 · granted JUN 18, 2019
Granted to Genovus Biotechnologies Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Genovus Biotechnologies INC | Louisville | CO | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.